electroCore Stimulates More Promise With Migraine Therapy
New research published in the Journal of Headache and Pain has demonstrated the potential of electroCore's noninvasive vagal nerve stimulation therapy for reducing menstrual migraine attacks by more than a third.
You may also be interested in...
Non-invasive neurostimulation specialist electroCore reorganizes top management roles as it embarks on next growth phase.
Electrocore, a company specializing in noninvasive vagal nerve stimulation (VNS), has appointed Dr Nader Youssef as Chief Medical Officer. Nader was previously Executive Director of GI Global Clinical Development and Medical Affairs for NPS Pharmaceuticals, where he was responsible for regulatory and development strategy and helped NPS secure US and EU marketing approvals for gastrointestinal drugs. Prior to NPS, he was at AstraZeneca, where his focus was also on GI pain and motility. His expertise in this area will be beneficial to electroCore as it expands its gammaCore noninvasive VNS platform to new indications within gastroenterology and other fields. gammCore was CE-marked in 2011 for treatment of migraine and cluster headaches.
Smith & Nephew has acquired Tusker Medical for an undisclosed price. The acquisition comes just months after Tusker’s Tula system was approved by the FDA as a breakthrough device.